References
Sjoblom, T. et al. Science 314, 268–274 (2006).
Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).
Castle, J.C. et al. Cancer Res. 72, 1081–1091 (2012).
Matsushita, H. et al. Nature 482, 400–404 (2012).
Robbins, P.F. et al. Nat. Med. 19, 747–752 (2013).
van Rooij, N. et al. J. Clin. Oncol. doi:10.1200/jco.2012.47.7521 (16 September 2013).
Vonderheide, R.H. et al. Nat. Med. 19, 1098–1100 (2013).
Terasaki, M. et al. J. Clin. Oncol. 29, 337–344 (2011).
Noguchi, M. et al. Prostate 72, 834–845 (2012).
Carbone, D.P. et al. J. Clin. Oncol. 23, 5099–5107 (2005).
Rahma, O.E. et al. J. Transl. Med. 8, 8 (2010).
Lifton, R.P. N. Engl. J. Med. 362, 1235–1236 (2010).
Rammensee, H.G. et al. Immunogenetics 41, 178–228 (1995).
Weinschenk, T. et al. Cancer Res. 62, 5818–5827 (2002).
European Medicines Agency. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products CHMP/SWP/28367/07; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf (EMA, London, 2007).
Acknowledgements
U.K. participated on behalf of the CIMT Regulatory Research Group. Twincore, Centre for Experimental and Clinical Infection Research, is a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.S.-J. is employee and shareholder of Immatics Biotechnologies GmbH, which has a commercial interest in development of cancer immunotherapies.
C.H. is co-founder, advisor and deputy-chairman of BioNTech. BioNTech develops highly individualized mutational epitope tumor vaccines.
Supplementary information
Supplementary Text and Figures
Supplementary Note (PDF 67 kb)
Rights and permissions
About this article
Cite this article
Britten, C., Singh-Jasuja, H., Flamion, B. et al. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31, 880–882 (2013). https://doi.org/10.1038/nbt.2708
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2708
- Springer Nature America, Inc.
This article is cited by
-
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Nature Reviews Clinical Oncology (2020)
-
Therapeutische Immunisierungen gegen Tumore und neurodegenerative Erkrankungen
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2020)
-
Indocyanine green and poly I:C containing thermo-responsive liposomes used in immune-photothermal therapy prevent cancer growth and metastasis
Journal for ImmunoTherapy of Cancer (2019)
-
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Nature Reviews Neurology (2017)
-
Advances in personalized cancer immunotherapy
Breast Cancer (2017)